EXTENDED REPORTS

The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment

V Kyle, B L Hazleman

Abstract

Objectives—To examine the clinical course of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in a prospective study, after the initial two months.

Methods—Seventy-four patients with PMR/GCA were followed for a median of 60 weeks. Detailed clinical and laboratory records were made on each visit.

Results—Twenty per cent of patients with PMR developed GCA and 24% of patients with GCA developed PMR from the onset of symptoms. After two months, most patients experienced at least one relapse. Relapses and persistence of abnormal symptoms and signs were most common in patients with both PMR and GCA and least common in those with GCA alone. Relapses were most common in the first year and 54% occurred in association with steroid reduction. Major complications were rare. Laboratory parameters and temporal artery histology were not helpful in predicting relapse. Only 24% of patients were able to stop steroid treatment after two years.

Conclusions—Clinicians should consider more frequent review in patients at times of steroid reduction and especially in the first six months of treatment.

(Ann Rheum Dis 1993; 52: 847–850)

The earliest case reports of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) emphasised that patients made a full recovery.1 2 Before corticosteroid therapy, however, patients with PMR were reported to have symptoms from three months to 35 years,3 with a mean disease duration of 7.1 years.4

Whilst studies from the USA report that most patients discontinued steroids in less than two years5 13 with a mean of 11 months treatment, European studies have suggested that most patients require steroids for at least two years. Fourteen to seventeen per cent discontinued steroids at 16 to 21 months and 40–45% discontinued treatment between 24 and 31 months.6–10 One study found only 16% of patients had stopped taking steroids at five years.11

It is well recognised that relapses, including loss of vision, can occur in patients who are well controlled on corticosteroids.7 14 The reported incidence of relapse ranges from 4–87% of patients and many experience more than one episode.9 10 13 15–19 Most relapses were related to steroid reduction;16 in one study the disease spontaneously became active.9 In two studies patients with PMR tended to have PMR flares10 17 but in another, 55% of PMR patients went on to develop GCA and 26% developed visual or neurological complications.18 Other groups reported that patients with either PMR or GCA usually had polymyalgic flares and that GCA patients had both polymyalgic and arteritic flares.17 Most groups agreed that relapses were more common during the first year of treatment. Two studies reported that the ESR was evaluated during 70%6 and 100%15 of relapses. Once treatment was discontinued, the reported relapse rate ranged from 4–43%.6 9 13 Patients tended to relapse within one year of stopping prednisolone8 9 17 but relapses after 10 years occurred.3

There is considerable variation in the reported frequency and nature of relapses. It is not clear why relapses occur, nor whether they can be predicted. The aim of this prospective study was to follow patients with PMR alone, GCA alone and with both conditions and document the course of their disease, with particular emphasis on relapses in each patient subgroup.

Patients and methods

Seventy-four patients with active untreated PMR/GCA were followed up for a median of 60 weeks. All fulfilled the diagnostic criteria of Jones and Hazleman (Appendix).18 Patients were allocated by clinical diagnosis as having PMR only, GCA only, or features of both PMR and GCA (‘Both’). Patients were reviewed fortnightly initially, then every 2–3 months. On each visit, muscle pain, stiffness or tenderness, headaches, scalp tenderness, temporal artery tenderness, pulsation and thickening and visual symptoms were graded on a scale from 0–2, and other symptoms or signs also recorded including blood pressure and weight. An overall clinical assessment was then made on each visit as follows:
Grade 1 — Relapse, either as a new event or if judged to have remained in relapse from the previous visit. Patients experiencing a relapse had developed symptoms and signs which were felt to require an increase in prednisolone dosage. PMR relapse included as a minimum, pain and stiffness in the shoulder or hip girdle; GCA relapse required headache with scalp or temporal artery tenderness noted on examination, or visual symptoms.

Grade 2 — Improvement from Grade 1 but symptoms/signs not fully resolved.

Grade 3 — Well, no significant symptoms/signs.

INITIAL TREATMENT

The prednisolone dose was controlled by the doctor not the patient but on some occasions, patients increased the dose of prednisolone between visits if they experienced a relapse. The treatment regime for the first two months has been previously reported.20 Patients with GCA took 40 mg prednisolone for five days then were randomly allocated to a low dose regime (20 mg for four weeks, 15 mg for two weeks then 10 mg for two weeks) or a high dose regime (40 mg for four weeks, 30 mg for two weeks, 20 mg for two weeks).

Patients with PMR were also randomly allocated to a high dose regime (20 mg prednisolone for one month, 15 mg for two weeks then 10 mg for two weeks) or low dose (10 mg prednisolone/month, 7-5 mg for two weeks then 5 mg for two weeks).

Steroid reduction was about 2.5 mg/month from 2-4 months, then about 1 mg/month for 4-12 months and 1 mg every 2-3 months thereafter. The current prednisolone dose and any planned alteration was recorded. Full blood count, ESR (Westergren) C reactive protein (nephelometry), orosomucoid, haptoglobin, α1 antitrypsin, immunoglobulins G, A and M, immune complexes (complement consumption) and alkaline phosphate were measured on every visit. A record was also kept of patients who relapsed between visits and of intercurrent illness.

STATISTICS

Results were analysed using Chi-squared tests, analysis of variance for the ESR values during relapses and Kruskal Wallis tests for length of follow up, number of visits and steroid dose on relapse in each subgroup.

Results

Thirty nine patients presented with PMR alone, 18 with GCA alone and 17 with both PMR and GCA (‘Both’). Seventeen were male. The mean age was 71.4 years. Sixty nine per cent of patients with PMR presented within four months of onset of symptoms and 65% of patients with GCA presented within two months of the onset. Fifty per cent of patients with ‘Both’ presented within four months but almost a third consulted their general practitioners more than a year after disease onset, usually because of the development of GCA symptoms some months after the onset of PMR. GCA preceded PMR in only two patients with both PMR and GCA.

There were 847 patient visits in total, with a range of 2-33 visits/patient (mean 11, SE 0-72). The mean length of follow up was similar in all three groups. Two patients (9%) with PMR developed GCA after the first two months of treatment; one at 26 weeks and one at 89 weeks (six also developed GCA within the first two months of treatment).20 Four patients with GCA developed PMR (24%) at 15, 27, 67 and 75 weeks after starting treatment.

The clinical course within the first two months of treatment has been discussed in a previous paper comparing different steroid regimes.20 Two patients were followed up for only eight weeks and one woman with florid GCA died at home at eight weeks. Follow up data was therefore available on 71 females (39 PMR, 16 GCA, 16 ‘Both’) after two months, with 4729 patient weeks of follow up and 574 patient visits. Patients with ‘Both’ were reviewed on a mean of ten occasions, PMR 7-5 visits and GCA 7-7 visits. There were 77 observed relapses in 43 patients (60%) after the first two months – 24 PMR (61%), eight GCA (25%), 11 ‘Both’ (50%). Forty one relapses between visits were reported by patients who had increased their prednisolone dose and were well when seen at the next visit. Thus only 27% of patients did not experience a relapse after the first two months. Most patients (77%) were observed to experience one or two relapses after two months but 10 had three or more (table 1).

In addition, there were 32 subsequent visits where symptoms remained as severe, that is, 101 Grade 1 visits. There were 74 visits after the initial two months when patients had improved from a relapse but were still not back to normal (Grade 2 visits).

There were significantly fewer abnormal visits (Grade 1 and Grade 2) in patients with GCA only (p < 0.01). This difference held when abnormal visits were considered as a percentage of weeks of follow up. If the relapse rate was considered with respect to the final diagnosis rather than the diagnosis on presentation, the same pattern was seen. Four patients (two PMR, two Both) accounted for 60 abnormal visits (Grade 1 and 2) but even if these atypical patients were excluded, patients with GCA alone had the fewest relapses and abnormal visits.

One patient with both PMR and GCA lost the sight in one eye while on treatment; ESR
Table 2 Frequency of symptoms and signs during relapses in each subgroup

<table>
<thead>
<tr>
<th>Symptoms/signs – Number of occurrences</th>
<th>Muscle pain</th>
<th>Muscle stiffness</th>
<th>Muscle tenderness</th>
<th>Headache</th>
<th>Visual symptoms</th>
<th>Tender scalp/temporal artery</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMR</td>
<td>33</td>
<td>32</td>
<td>19</td>
<td>13</td>
<td>3</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>GCA</td>
<td>6</td>
<td>4</td>
<td>0</td>
<td>8</td>
<td>1</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>BOTH</td>
<td>6</td>
<td>4</td>
<td>2</td>
<td>11</td>
<td>10</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>ALL</td>
<td>45</td>
<td>40</td>
<td>21</td>
<td>32</td>
<td>14</td>
<td>23</td>
<td>8</td>
</tr>
</tbody>
</table>

Table 3 Mean prednisolone dosage (mg) with time

<table>
<thead>
<tr>
<th>PMR</th>
<th>Number of patients</th>
<th>GCA + Both</th>
<th>Number of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose (Range)</td>
<td></td>
<td>Dose (Range)</td>
<td></td>
</tr>
<tr>
<td>6/12</td>
<td>8-68 (5-15)</td>
<td>37</td>
<td>10-60 (5-20)</td>
</tr>
<tr>
<td>1 year</td>
<td>7-10 (2.5-12.5)</td>
<td>25</td>
<td>7-38 (2.5-15)</td>
</tr>
<tr>
<td>16/12</td>
<td>5-82 (2-15)</td>
<td>14</td>
<td>5-38 (0-10)</td>
</tr>
<tr>
<td>2 years</td>
<td>6-90 (0-20)</td>
<td>9</td>
<td>8-05 (10-40)</td>
</tr>
<tr>
<td>3 years</td>
<td>7-5 (0-20)</td>
<td>3</td>
<td>5-6 (2-5)</td>
</tr>
</tbody>
</table>

Discussion

This study suggests that PMR/GCA runs a benign course in most patients but at least one episode or relapse was common. Serious complications were rare. Although 20% of patients with PMR developed GCA after treatment was started, three quarters did so within the first five weeks. It would be prudent to review patients frequently in the first eight weeks of treatment, so that the development of GCA would be detected rapidly. The low incidence of late development of GCA is reassuring. Definition of relapse is inevitably arbitrary, in this study a pragmatic view was taken: a recurrence of symptoms severe enough to warrant an increase in prednisolone dose was defined as relapse, irrespective of the ESR or CRP. Almost all patients were directly referred by their general practitioners who would normally have managed at least half of these cases at home. This study therefore is closer to a true population study than most. This may partly account for the lower incidence of serious complications compared with other retrospective studies. A previous study in the same hospital found a much higher complication rate, probably because it dealt with a selected population many of whom had been seen by physicians, neurologists or ophthalmologists, and who may have had a more aggressive disease.

We confirmed the finding of other studies that relapses were most frequent within the first few months after diagnosis. About half of the relapses occurred in relation to attempted steroid reduction usually at a dose of around 10 mg. We suggest that clinicians should
review patients more frequently when reduction below 10 mg of prednisolone is attempted. Patients with both GCA and PMR had more frequent relapses and persistence of symptoms, and the difference was most striking when compared with those with GCA only. This has not been documented previously although most studies have not separated GCA alone from GCA with PMR and thus may have missed this observation. These patients were more likely to experience arteritic flares, so the phenomenon of ‘pseudorheumatism’, seen on steroid reduction, was not the explanation for the increased number of abnormal visits in this group. The number of visits/patient and mean follow up was not significantly different in each subgroup, so these findings are not due to unwell patients being seen more often. The initial response to steroid treatment when higher doses were used was rapid in most cases; relatively small increases in prednisolone dose were given during relapses and it is possible that a larger increase would have led to more rapid recovery. There was no evidence that the different initial treatment regimes influenced relapses later in any subgroup. Some patients, especially those with PMR, preferred to tolerate mild symptoms rather than increase their steroids further.

We examined the data to see if particular characteristics such as age, temporal artery histology, initial ESR or other laboratory features such as, alkaline phosphatase predicted relapse, but found no such association. About a third of patients with ‘Both’ had symptoms for over a year before treatment; numbers in this group were small and did not appear to be more at risk of relapse.

The acute phase proteins were not of value in assessing disease activity, and the results support an earlier study where osoromucoid and haptoglobin but not ESR tended to remain elevated despite clinical improvement. Elevation of alkaline phosphatase or immune complexes was rare after treatment was started.

The number of patients able to discontinue steroids was small and could not be formally analysed, but no clinical or laboratory features appeared to predict the early withdrawal of steroids. Our results support the European view that treatment is needed for at least two years in most cases. Longer follow up would be helpful in future studies to clarify the length of treatment needed and the frequency of later relapses.

Appendix

Diagnostic criteria for PMR/GCA

Criteria for diagnosis of PMR
1 Shoulder and pelvic girdle pain which was primarily muscular in the absence of true muscle weakness.
2 Morning stiffness.
3 Duration of at least two months unless treated.
4 ESR over 30 mm/h or C-reactive protein (CRP) over 6 µg/ml.
5 Absence of rheumatoid or inflammatory arthritis or malignant disease.
6 Absence of objective signs of muscle disease.
7 Prompt and dramatic response to systemic corticosteroids.

Criteria for diagnosis of GCA
1 Positive temporal artery biopsy or cranial artery tenderness noted by a physician.
2 One or more of the following: visual disturbance, headache, jaw pain, cerebrovascular insufficiency.
3 ESR over 30 mm/h or CRP over 6 µg/ml.
4 Response to corticosteroid.

If a patient with PMR receiving corticosteroids developed symptoms of GCA, a raised ESR or CRP would be considered necessary for the diagnosis of GCA.

2 Hutchinson J. Diseases of the arteries No 1. On a peculiar form of thromboid arteritis of the aged which is sometimes productive of gangrene. Archives of Surgery 1890; 2: 323–9.